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ABSTRACT
MeCP2 is a nuclear protein that binds to sites of cyto-
sine methylation in the genome. While most evidence
confirms this epigenetic mark as the primary deter-
minant of DNA binding, MeCP2 is also reported to
have an affinity for non-methylated DNA sequences.
Here we investigated the molecular basis and in
vivo significance of its reported affinity for non-
methylated GT-rich sequences. We confirmed this
interaction with isolated domains of MeCP2 in vitro
and defined a minimal target DNA sequence. Binding
depends on pyrimidine 5′ methyl groups provided
by thymine and requires adjacent guanines and a
correctly orientated A/T-rich flanking sequence. Un-
expectedly, full-length MeCP2 protein failed to bind
GT-rich sequences in vitro. To test for MeCP2 bind-
ing to these motifs in vivo, we analysed human neu-
ronal cells using ChIP-seq and ATAC-seq technolo-
gies. While both methods robustly detected DNA
methylation-dependent binding of MeCP2 to mCG
and mCAC, neither showed evidence of MeCP2 bind-
ing to GT-rich motifs. The data suggest that GT bind-
ing is an in vitro phenomenon without in vivo rele-
vance. Our findings argue that MeCP2 does not read
unadorned DNA sequence and therefore support the
notion that its primary role is to interpret epigenetic
modifications of DNA.
INTRODUCTION
The DNA base cytosine can exist in a variety of mod-
ified forms of which 5-methylcytosine (mC) is the most
abundant in vertebrates (1). Cytosine methylation is im-
plicated in regulation of a variety of molecular processes,
including transcription and chromosome organization (2).
In most cell types cytosine modification occurs almost ex-
clusively at the dinucleotide CG, but in brain the dinu-
cleotide CA is also highly methylated particularly within
the trinucleotide CAC (3,4). The 5-methylcytosine binding
protein MeCP2 is also present at high levels in neuronal
cells (5) where it interacts with both methyl-CG (mCG)
and methyl-CAC (mCAC) (6–8). A primary function of
MeCP2 is to recruit the NCoR1/2 corepressor complex to
these methylated sites and thereby restrain neuronal tran-
scription (6,8–10). Mutations compromising either DNA
binding or corepressor recruitment cause the severe neu-
rological disorder Rett syndrome, emphasizing the impor-
tance of this role (9,11). Discrete protein domains respon-
sible for methyl-CpG/mCAC binding (the methyl-binding
domain: MBD) and NCoR1/2 interaction domain (NID)
have been defined by deletion analysis and X-ray crystallog-
raphy of the protein–DNA and protein–protein complexes
(9,12–14). Importantly, these two domains alone are suffi-
cient to rescue survival of MeCP2-deficient mice (15).
Most studies confirm the pivotal importance of DNA
methylation in determining the MeCP2 interaction with
chromatin (5,7,8,16,17), but evidence that other features
of DNA sequence can be recognized has been presented
(see (18)). These findings question the notion that MeCP2
is predominantly a ‘reader’ of the epigenetic DNA methy-
lation mark. If non-methylated sites were to be promi-
nent among its targets, MeCP2 could be viewed less as a
reader of the epigenome, which varies in different devel-
opmental cell lineages, and more of a conventional tran-
scription factor that interprets the unchanging DNA se-
quence. Thus, interpretation of MeCP2 function is strongly
affected by whether it is instructed by the epigenome alone
or also by the genomic base sequence. To investigate the
significance of DNA methylation-independent binding, we
chose to re-visit the best-characterized example of a specific
non-methylated DNA sequence that is targeted by MeCP2.
Early in vitro experiments established that an N-terminal
fragment of chicken MeCP2 bound with high affinity to
several DNA sequences that typically contained a GT-
rich sequence, often flanked by an A/T-run (19,20). Re-
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cently a structure of the MeCP2 MBD in complex with
GTG(T)-containing DNA has been solved (21). Using hu-
man MeCP2 we defined GT-rich sequences that can in-
teract with domains of MeCP2 and showed that bind-
ing depends on guanine and the pyrimidine methyl group
provided by thymine. Unexpectedly, the full-length protein
failed to exhibit detectable DNA methylation-independent
binding in vitro, suggesting that this may be a property
only of MeCP2 sub-fragments. We therefore tested MeCP2
binding to GT-rich motifs in vivo. Using independent as-
says based on chromatin immunoprecipitation-sequencing
(ChIP-seq) and transposase accessible chromatin sequenc-
ing (ATAC-seq), we were unable to detect this mode of
MeCP2 binding, even when MeCP2 was expressed at high
levels. These results suggest that GT-rich binding is an in
vitro phenomenon that is not relevant in vivo. They there-
fore strengthen the likelihood that symmetrically methy-
lated mCG and asymmetrically methylated mCAC are the
primary recognition modules for MeCP2 in living cells.
MATERIALS AND METHODS
Recombinant MeCP2 expression and purification
Recombinant human MeCP2 protein was fused to a C-
terminal histidine tag, to facilitate purification, and ex-
pressed from the vector pET30b. Plasmids expressing
MeCP2[1-205]; MeCP2[77-167]; and MeCP2[1-486] were
constructed as described previously (29). Proteins were pro-
duced in bacteria using standard procedures as described
(22) (see Figure 1A).
Oligonucleotide probes
Synthetic DNA oligonucleotides (Biomers, Germany) were
based on a 58 bp parent probe derived from promoter III
of the mouse Bdnf locus whose crystal structure in con-
junction with MeCP2[77-167] has been solved (12). The se-
quence contains a central mCG motif followed at the 3′-
end by an A/T-flank. In some experiments, the CG or A/T-
flank were substituted with the sequences indicated in Table
1. Single-stranded oligonucleotides were annealed and end-
labelled with T4 polynucleotide kinase (NEB) and 32P- -
ATP (Perkin Elmer). For pull-down assays the parent DNA
sequences were as described in (23) with the adjustments de-
scribed in Table 1.
Electrophoretic mobility shift assay
Labelled DNA probe (1 ng) and 1 g poly deoxyadenylic-
thymidylic acid (polydA-dT) competitor (Sigma-Aldrich)
were co-incubated on ice for 30 min with the indicated
amount of MeCP2 in a 20 l reaction volume containing 10
mM Tris–HCl, pH 7.5; 150 mM KCl, 0.1 mg/ml BSA; 5%
glycerol; 0.1 mM EDTA. In the case of MeCP2[1–486], re-
actions were performed in 250 mM KCl (24). Samples were
resolved on a chilled 10% TBE-acrylamide gel run at 100 V
for 70 min in TBE. Gels were exposed to a phosphor screen
overnight and imaged using a Typhoon FLA 9500 scan-
ner (GE Healthcare). Where indicated the amount of probe
bound by recombinant MeCP2 was quantified, in triplicate,
using ImageJ software.
DNA pull-down assay
This assay was essentially as described (23) with the follow-
ing modifications. PCR-generated, biotin end-labelled 147
bp DNA probes (2 g) were coupled to M280-streptavidin
Dynabeads according to the manufacturer’s instructions
(Invitrogen). In the case of CG and CAC these motifs were
either non-methylated or methylated (see Table 1 for se-
quences). Bead-DNA complexes were then co-incubated
with 20 g of rat brain nuclear protein extract (25) for 1.5
h at 4◦C. Following extensive washing, bead-bound pro-
teins were eluted using Laemmli buffer (Sigma) and re-
solved on a 4–15% SDS-polyacrylamide gel (NEB). The
presence of MeCP2 was assayed by western blot using anti-
MeCP2 monoclonal antibody M6818 (Sigma); with sec-
ondary detection employing IR-dye secondary antibodies
(IRDye 800CW donkey anti-mouse, LI-COR Biosciences)
then scanned using a LI-COR Odyssey machine.
Generation of LUHMES cell lines expressing various levels
of MeCP2
The procedure for culture and differentiation of the
LUHMES (Lund Human Mesencephallic) cell line was pre-
viously described in (26). LUHMES cells expressing various
levels of MeCP2 expression have been described in (10).
Illumina sequencing and data analysis
The ChIP-seq, ATAC-seq and bisulfite mapping were per-
formed as described (10). The data reported in this pa-
per were deposited in the Gene Expression Omnibus
(GEO) database, www.ncbi.nlm.nih.gov/geo (accession no.
GSE125660). Trimmomatic version 0.32 was used to per-
form quality control on 94 and 75 bp paired-end reads
to remove adapter sequence and unreliable reads for both
TAB-seq and ChIP-seq. For TAB-seq, we used Bismark
version 0.10 to further align and process the reads. Map-
ping was performed in bowtie2 mode to the human hg19
reference genome. Following alignment, duplicated reads
were removed and methylation values were extracted as
Bismark coverage and cytosine context files. We calculated
the methylation percentage at each cytosine position as
(mC/C)x100 and generated *.bed files for further process-
ing. Bwa mem version 0.7.5 was used to map reads to
the human hg19 reference genome. We filtered the align-
ments to remove reads that map to multiple locations in
the genome and to blacklisted regions defined by the EN-
CODE project. We further removed duplicate reads with Pi-
card version 1.107 MarkDuplicates (http://broadinstitute.
github.io/picard/). To account for varying read depths we
used deepTools version 2.5.1 to create bigWig files nor-
malised by RPKM (reads per kilobase per million reads). To
quantify MeCP2 occupancy on the genomic features of in-
terest (mCG, mCA, GT, etc.), we rejected reads longer than
1 kb as alignment artefacts.
ChIP-seq enrichment analysis
We used the EMBOSS tool dreg to find all instances of GT
motifs in the hg19 reference sequence with a downstream
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Figure 1. MeCP2 [1–205] binds to non-methylated GT-rich DNA in vitro and requires a methyl group provided by thymine. (A) Coomassie stained gel of
purified recombinant proteins used in this study, full-length MeCP2[1–486], MeCP2[1–205] and MeCP2[77–167]. M = protein standard (Precision Plus,
Bio-Rad). (B) Schematic diagram of the fragments of MeCP2 used here and in earlier studies. The lower diagrams show fragments of chicken MeCP2
tested previously for binding to GT-rich sequences (MAR) with high affinity, indicating whether GT binding was detected (20). The human MBD (grey
shading) is located between amino-acids 78 and 162 (14). The highly homologous chicken MBD (also grey) extends from amino-acid 79 to 163. (C) EMSAs
using varying amounts of MeCP2[1–205] or no protein (−) with probes containing non-methylated CG (CG), methylated CG (mCG), methylated CAC
(mCAC) or GGTGT. (D) Graph showing quantification of MeCP2[1–205] binding to probes containing CG (filled squares), mCG (filled circles), mCAC
(filled triangles) or GGTGT (crosses). Mean percentage of probe shifted (±SEM) based on triplicate experiments. (E) EMSAs using no protein (−) or
varying amounts of MeCP2[1–205] with probes containing GGTGT, GGUGU, GGUGT or GGTGU to assess the influence of the thymine methyl group
on binding.
Overlapping motifs were merged and we selected 50 bases
± the start of each region using BEDTools. The average
methylation state and read coverage of each region was cal-
culated using bigWigAverageOverBed in conjunction with
the processed BS-seq data. Regions with mean read cov-
erage <10 were dropped and the remaining regions were
subsetted based on the mean methylation percentage of all
cytosine (mC%). Non-methylated regions were classified as
mC% = 0 while methylated regions were defined as mC%
> 10. We then plotted the relative enrichment of MeCP2
ChIP (WT and OE 11x) versus KO in 100 base bins across
methylated and non-methylated regions for each GT motif
as well as a set of control motifs (GGGTTT, TTTGGG).
The relative enrichment is the log2 ratio of normalised read
counts of MeCP2 ChIP versus KO ChIP scaled to the mean
of the three flanking bins on either side of the plot. Next,
we calculated the local GC% of each region by quantifying
average GC% across the 2 kb plotted region. All filtering
and plotting were performed in R using the base packages
as well as genomation, seqplots and ggplot2.
ATAC-seq footprint analysis
We obtained insertion profiles as described (10). The po-
sitions of insertions were accumulated to create insertion
count profiles centred at different genomic features: (i)
mCA, (ii) CA, (ii) GTGT, GGTGT (irrespectively of methy-
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Table 1. Oligonucleotides used in this study













































m = methylated. All molecules were annealed to the appropriate methylated or non-methylated reverse oligonucleotide.
To calculate the relative insertion probability profiles and













where nsamplei and n
KO
i are the insertion counts profiles
for the MeCP2 OE 11x and MeCP2 KO, respectively,
and Norm2 normalizes the counts profiles such that their
flanks (–50. . . –41 bp and +41. . . 50 bp) have values close to
one:
Norm2 (ni ) = ni(∑−41






To simulate ATAC-seq, we used the MeCP2 binding and
ATAC-seq model from (10) (binding to motifs mCGx and
mCAx where x = A, C, G, T, with different affinities) with
the following changes: (i) we simulated the same number of
insertions as in the experimental KO data, (ii) we simulated
insertions in all chromosomes, (iii) we assumed that MeCP2
could also bind to non-methylated GTGT with a fraction x
of the mCG binding probability p. We simulated KO (p =
0) and OE 11x (p = 0.063 according to (10)).
To estimate the GTGT binding strength x relative to
mCG binding we used Bayesian inference. We previously
showed (10) that motif occupancy can be estimated from
the difference r between relative insertion probabilities fi in


















We calculated r for our data (mean of two replicates
for OE 11x/KO) and used computer simulations described
above to obtain Bayesian posterior probability distribution
of x that would give the same r , assuming uniform prior on
x. In this analysis, we used all GGTGT motifs irrespectively
of their methylation. We did this to increase the number of
analysed motifs, as the number of GGTGT motifs devoid
of methylation is only 20% of the total which would reduce
the statistical power of our analysis. In fact, most motifs
are only weakly methylated: 44% of all regions have mean
methylation <10%, with less than 1% motifs having mean
methylation >20%. Since our computer model explicitly in-
cludes MeCP2 binding to methylated C, any (small) contri-
bution from mC binding to r is accounted for when com-
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RESULTS
Nucleotide determinants of cytosine methylation-
independent DNA binding by MeCP2
To investigate the molecular basis of MeCP2 binding to
non-methylated DNA in vitro we performed electrophoretic
mobility shift assays (EMSAs) using a recombinant N-
terminal fragment of MeCP2 comprising amino-acids 1–
205 (see Figure 1A for gel analysis of proteins used in this
study). MeCP2[1–205] includes the entire MBD (14) and
sequences corresponding to a region of chicken MeCP2
(amino-acids 72 to 196) shown by Strätling and colleagues
to bind non-methylated GT-rich DNA sequences (19,20)
(Figure 1B). In comparative EMSAs, a non-methylated
duplex probe containing GGTGT (Table 1) bound to
MeCP2[1–205] (Figure 1C). By this semi-quantitative assay,
the binding affinity was comparable to that of a probe con-
taining mCAC, but lower than the classical MeCP2 recog-
nition sequence mCG (Figure 1D). Our results confirm that
binding of chicken MBD to this non-methylated sequence
in vitro is replicated with the human protein.
A previous study showed that the interaction of MeCP2
with mCAC, whose complement is GTG, depends on the
cytosine methyl-group, but also on the methyl group pro-
vided by thymine. Binding was abolished by substitution
of T, which is base-paired to the central adenine of CAC,
by uracil (U), which lacks the 5′ methyl group (8). We
asked whether thymine methyl groups in the GGTGT se-
quence were also necessary for binding. Synthetic probes
in which both thymines (T) were substituted with U
(oligo:GGUGU) showed strongly impaired binding (Fig-
ure 1E). Probes in which only the central thymine was sub-
stituted by U (oligo:GGUGT) showed a similar reduction,
suggesting that this methyl group is essential for binding,
whereas mutating the 3′ T to U (oligo:GGTGU) had only a
marginal effect. Thus, the pyrimidine methyl group on the
central thymine of the pentanucleotide motif is critical for
cytosine methylation-independent binding by MeCP2.
As an N-terminal fragment of chicken MeCP2 can also
bind to the sequence GTGTGT [GT3] (20), we used EM-
SAs to examine the effect of GT dinucleotide repeat length,
from GT1 to GT5, on MeCP2[1–205] binding. Neither GT1
nor GTG (CAC on the complementary strand) bound sig-
nificantly in EMSAs, but GT2–5 bound with similar affin-
ity to GGTGT and mCAC, (Figure 2A). This suggests
that GTGT is the minimal core MeCP2 target sequence in
vitro. Alteration of bases at positions 1, 3 and 4 of this se-
quence showed that any deviation from GTGT greatly re-
duced binding by MeCP2[1–205] (Figure 2B). Background
binding to CAC, base-paired with GTG, shows that the un-
modified trinucleotide fails to interact by this assay (Figure
2A, B, bottom panels). In addition, we found that probe
sequences flanking GTGT had a strong effect on in vitro
binding affinity, as simply inverting the GTGT motif within
an otherwise unchanged probe diminished binding (Fig-
ure 2C). Also, as reported for chicken MeCP2 (19), replac-
ing a neighbouring AT-rich sequence in the original probe
by a more GC-rich sequence greatly reduced the interac-
tion (Figure 2D). The results demonstrate that the complex
formed between MeCP2[1–205] and GT-rich DNA is highly
sensitive to the flanking DNA sequences.
Cytosine methylation-independent DNA binding requires
specific fragments of MeCP2
GTGT binding, like mCG and mCAC binding, depends
on a functional MBD, as mutation of the crucial arginine
residue R111 to glycine abolished the interaction ((21) and
data not shown). To determine more precisely whether the
protein domains required for mCG binding and GGTGT
binding are co-extensive we performed EMSAs using the
minimal mCG-binding domain, MeCP2[77–167], whose
structure in complex with methylated DNA was solved pre-
viously (12). MeCP2[77–167] bound to mCAC as expected,
but the interaction with GGTGT was surprisingly reduced
to near background levels (Figure 3A, B). These data agree
with the earlier finding that that protein sequences imme-
diately C-terminal to the minimal MBD are required for
MeCP2 to interact with DNA in a mC-independent fash-
ion in vitro (19). We next examined the ability of full-length
MeCP2 to bind probes containing GGTGT, CG and mCG.
As reported previously, MeCP2[1–486] shows reduced dis-
crimination between mCG and CG in EMSAs compared
with shorter MBD-containing fragments, as non-specific
DNA binding increases using this assay (27). Despite this
limitation, we detected a reproducible preference for bind-
ing to mCG compared with CG (Figure 3C, D). GGTGT-
binding, however, was indistinguishable from that observed
with non-methylated CG (Figure 3C, D). Due to the high
background in the EMSA assay, we adopted an alternative
‘pull-down’ assay whereby brain extracts were incubated
with PCR-generated probes containing multiple CG, CAC,
mCG, mCAC, GTGT or GGTGT motifs (see Table 1 for
sequences) that were immobilised on beads (23,25). West-
ern blots detected strong retention of MeCP2 with mCG
and mCAC, but no MeCP2 was recovered with CG, CAC,
GTGT or GGTGT probes (Figure 3E). The results con-
firm that the affinity for GTGT seen with the MeCP2[1–205]
sub-fragment in vitro is not a property shared by the intact
protein.
MeCP2 does not detectably bind to GT-rich sequences in vivo
The dependence of GT-motif binding on the surround-
ing DNA sequence context and on which domains of
MeCP2 are tested made it critical to assess the relevance
of this interaction in vivo. For this purpose, we interrogated
MeCP2 ChIP-seq data derived from cultured human neu-
rons (LUHMES cells) with varying levels of MeCP2 (10).
These cells give rise to immature neurons with low levels of
mCAC, which is advantageous when investigating MeCP2
binding to non-methylated CAC-containing motifs. A pre-
vious study showed enrichment of bound MeCP2 at mCG
using ChIP-seq and also detected robust footprints at this
methylated motif using ATAC-seq (10). We first searched
the human reference genome for non-overlapping GTGT
and GGTGT motifs with a 3′ run of A or T at least two
base-pairs long within 13 bases and identified more than
10,000 examples of each (see Table 2). Excluding the few re-
gions with low read coverage in whole genome bisulfite se-
quencing (TAB-seq) data (coverage < 10), motifs were then
classified as either ‘non-methylated’ if no mC was detected
within a 100 base-pair window surrounding the motif start
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Figure 2. DNA sequence determinants of cytosine methylation-independent binding by MeCP2. (A) EMSAs using varying amounts of MeCP2[1–205] or
no protein (−) with double-stranded oligonucleotide probes containing CAC, mCAC, GGTGT, GT1, GT2, GT3, GT4 or GT5 (see Table 1) to assess the
influence of GT-length on binding. Note that CAC is the complement of GTG, indicating that this trinucleotide motif does not bind MeCP2[1–205]. (B)
EMSAs in which MeCP2[1–205] was incubated with oligonucleotide probes altered at either the first (XTGT), third (GTXT), or fourth (GTGX) positions
in the presence of varying amounts of MeCP2[1–205] or no protein (−). Probes containing GT1 or GT3 were used as negative and positive controls,
respectively. (C) Determination of the effect of DNA sequences flanking GTGT binding to MeCP2. EMSAs using varying amounts of MeCP2[1–205] or
no protein (−) with probes containing GT1, GT2, GT3 or GT2-inv bot (GT2-inverted indicated by yellow highlighting and inverted arrow). (D) The effect
of altering the base composition of the 3′-AT-flank adjacent to GTGT was assayed by EMSAs using varying amounts of MeCP2[1–205] or no protein
(−) with probes containing GT1, GT2, GT3 or GT2-A/T mut in which the TT-, AA- and AA-dinucleotides 3′-adjacent to GTGT were substituted by CG
(yellow highlight).
analysis yielded several thousand motifs of each kind (Table
2).
MeCP2-dependent ChIP enrichment at GT-rich motifs
was tested by comparing MeCP2 ChIP-seq data from cells
expressing wild-type levels of MeCP2, cells over-expressing
MeCP2 at 11x the wild-type level, and cells in which the
MECP2 gene had been knocked-out (Figure 4A). A meta-
analysis that plotted mean normalised ChIP-seq levels de-
tected a peak of binding at both mCG and mCAC sur-
rounded by a 100 base pair window that is otherwise
non-methylated (Figure 4B). No peak of binding to non-
methylated CG or CAC was present. A related analysis of
GT-rich motifs lacking mC failed to detect MeCP2 binding
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Figure 3. Cytosine methylation-independent binding requires specific fragments of MeCP2. (A) EMSA using varying amounts of MeCP2[77–167] or no
protein (−) with probes containing non-methylated CG (CG), methylated mCG (mCG), methylated CAC (mCAC) or GGTGT. (B) Graph quantifying
MeCP2[77–167] binding to probes containing CG (squares), mCG (circles), mCAC (triangles), or GGTGT (crosses). Mean percentage of probe shifted
(±SEM) based on triplicate experiments. The results with the minimal MBD may be compared with those for MeCP2[1–205] in Figure 1C and D. (C)
Full-length MeCP2[1–486] has a diminished ability to bind GGTGT. EMSAs using varying amounts of MeCP2[1–486] or no protein (−) with probes
containing non-methylated CG, methylated CG (mCG), or GGTGT. (D) Graph showing quantification of MeCP2[1–486] binding to probes containing
mCG (filled circles), non-methylated CG (filled triangles), or GGTGT (filled squares). Mean percentage of probe shifted (±SEM) based on triplicate
experiments. Statistical significance was measured between mCG and GGTGT: *P < 0.05, **P < 0.01 and ***P < 0.001 (unpaired two-tailed t-test).
The results with full-length MeCP2 may be compared with those for MeCP2[1–205] in Figure 1C and D. (E) Western blots with anti-MeCP2 antibody
following DNA pull-down from rat brain nuclear extracts using immobilised DNA sequences containing CG, CAC, mCG, mCAC, GTGT, GGTGT. Left
panel shows MeCP2 eluted from beads. Right panel shows that MeCP2 is present in all of the bead supernatants following pull-down. M = protein marker
(Page-Ruler, Thermo Scientific).
Table 2. Number of GT-rich motifs analysed. Methylated and non-
methylated columns show the number of sequences that passed the thresh-
olds applied for read coverage, methylation level etc (see Materials and
Methods). The Total column refers to the total number of GT-rich se-
quences found in the reference genome
Methylated motif Non-methylated motif Total
GGTGT 7131 6049 153 588
GTGT 7130 5485 124 803
that GT-rich regions associated with one or more mCG or
mCAC motifs within the surrounding 100 base pair window
displayed a coincident MeCP2 ChIP peak (Figure 4C). A
negative control was provided by the motifs GGGTTT and
TTTGGG, which are not expected to bind MeCP2. They,
like GT-rich motifs, failed to show ChIP peaks unless there
was a methylated site nearby (Figure 4D). Summit analy-
sis of ChIP peaks cannot be interpreted as a quantitative
measure of binding, as we noted previously that peak height
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Figure 4. Native MeCP2 is not enriched at GT-rich sequences in vivo. (A) Western blot showing expression level of MeCP2 in WT, MECP2 knockout (KO)
and 11-fold over-expressing (OE 11x) human neuronal cells in culture (see reference (10)). Replicates are independent cloned cell lines. (B) Composite plots
showing log2 enrichment of MeCP2 over windows containing methylated or unmethylated CG (red broken or solid lines, respectively) and methylated
or unmethylated CAC (blue broken or solid lines, respectively) that are otherwise free of methylation. (C) Composite plots showing log2 enrichment of
MeCP2 over GTGT- containing (grey) and GGTGT-containing (black) windows that do (dashed lines) or do not (solid lines) contain cytosine methylation
elsewhere. WT (left panel) and OE 11x (right panel) reads are normalised to KO. (D) Composite plots showing log2 enrichment of MeCP2 over windows
containing GGGTTT (grey) and TTTGGG (black) that do (dashed lines) or do not (solid lines) contain cytosine methylation elsewhere. WT (left panel)
and OE 11x (right panel) are normalised to KO.
fore, the variable peak heights associated with mCAC and
GTGT when part of a methylated fragment do not imply
differential affinities. Overall, the ChIP data offer no sup-
port for the notion that MeCP2 binds non-methylated GT-
rich sequences in vivo.
We complemented MeCP2 ChIP-seq enrichment analysis
with an independent assay that relies on ATAC-seq in vivo
footprint analysis (Figure 5A). Here a consistent position of
bound MeCP2 is essential for visualisation of the footprint,
as variably dispersed binding sites would not be detected.
To validate the method, we first calculated enrichment pro-
files over methylated and non-methylated CA in LUHMES
cells overexpressing MeCP2 11-fold. We previously showed
a clear footprint over mCG in this cell line (10). As expected,
the MeCP2 footprint is also observed over methylated CA
(Figure 5B left), but absent at non-methylated CA (Figure
5B, right). If the in vivo MeCP2 binding to GTGT was as
strong as the in vitro MBD binding, we would therefore ex-
pect to see a footprint on GTGT-containing sequences. To
check this, we looked for MeCP2 footprints on all GTGT
and GGTGT sequences, irrespective of methylation, and
used computer modelling to factor out contributions from
mCG and mCA binding. Figure 5C, D shows the absence
of a footprint on GTGT and GGTGT in OE 11x LUHMES
cells, in agreement with ChIP-seq in vivo data. Figure 5E
shows the Bayesian posterior probability of MeCP2 bind-
ing GTGT with probability x relative to that for mCG. The
probability peaks close to zero which is consistent with ab-
sent or very weak binding to GTGT (x < 0.29 of that for
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Figure 5. Absence of an ATAC-seq footprint of MeCP2 at GT-rich sequences in native chromatin. (A) A schematic representation of the ATAC-seq
procedure and footprint analysis. (B) ATAC-seq insertion profile shows a MeCP2 footprint over mCA (left) but no footprint over non-methylated CA
(right). (C) and (D) Absence of footprint at GTGT (left) and GGTGT (right), respectively. (E) Bayesian posterior probability distribution (P[x]) of the
GTGT binding probability versus GTGT binding strength relative to mCG binding (x) that best reproduces the experimental ATAC-seq insertion profile.
For comparison P[x] for mCA is shown (dotted line).
DISCUSSION
We re-investigated early reports that MeCP2 binds non-
methylated GT-rich DNA sequences in vitro (19,20), which
raised the possibility that GT-rich sequences are physio-
logical ligands of MeCP2 (21). Our results confirmed that
a sub-fragment of MeCP2 protein (MeCP2[1–205]) has a
high affinity for the minimal target sequence GTGT. They
also confirmed that binding depends upon a correctly orien-
tated AT-rich flanking sequence and showed that a 5′ pyrim-
idine methyl group must be supplied by thymine. Unexpect-
edly we found that neither an isolated MBD polypeptide
(MeCP2[77–167]) nor full-length MeCP2[1–486] supports
the GT-rich mode of binding to a level above background
in vitro. In apparent disagreement with this finding, a re-
cent crystal structure of the minimal MBD complexed with
a GTG(T)-containing DNA duplex has been determined
(21). We note, however, that the dissociation constant re-
ported for that interaction is 3–4 M, which is an order of
magnitude weaker than binding to mCG (21,28) and close
to the background affinity of the MeCP2 MBD for any
DNA sequence (28). Presumably this weak interaction was
favoured by the high concentrations of DNA and protein
in the crystallisation liquor. Our evidence that the minimal
MBD shows background binding to GTGT is consistent
with the published report (21) that GTGT binding by the
isolated MBD in vitro is much weaker than its affinity for
mCG or mCAC.
We found that MeCP2[1–205] showed GTGT binding,
but MeCP2[77–167] (the minimal MBD) bound this se-
quence very weakly. Previous work showed that the addi-
tion of seven amino acids C-terminal to the minimal MBD
reduced mC-dependent DNA binding and increased non-
specific interactions with DNA (14). The recent structure of
the low affinity (∼4 M) complex between CAC (which is
the complement of GTG) and the minimal MBD (21) does
not explain why the extra amino acids C-terminal should
facilitate binding of the 1–205 fragment or why this effect is
lost in the full-length protein. Previously published struc-
tures, which only involve domains corresponding to the
minimal MBD (77–167), suggest that DNA binding is ac-
companied by subtle conformational changes which may in-
fluence this interaction, but do not provide information on
interactions with the rest of the protein (12,29). As our study
revealed no evidence for GTGT binding to intact MeCP2,
we do not consider that a detailed mechanistic understand-
ing of this binding mode is a high priority.
Due to the inherent limitations of in vitro studies with
purified components, we employed two independent in vivo
assays to look for MeCP2 binding to GT-rich sequences in
vivo. Using a human neuronal cell-line engineered to con-
tain differing levels of MeCP2 we analysed ChIP-seq and
ATAC-seq data (10). We verified that MeCP2 generates a
ChIP peak and also a cytosine methylation-dependent foot-
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Neither method of analysis detected evidence of MeCP2
binding to non-methylated GTGT or GGTGT motifs in
vivo. In spite of this negative result, we cannot formally ex-
clude the possibility that a subset of GT-rich sequences,
below the detection limit of our assays, associates with
MeCP2 in vivo. For example, changes to the sequence en-
vironment of GTGT may enhance binding. While we can-
not disprove this possibility, several factors argue against
it. Firstly, GGTGT is a subset of the simplest GTGT in
vitro target sequence but tested negative for binding here.
Secondly, for our in vivo analysis we imposed the condi-
tion that there must be a nearby AT-rich flanking sequence,
as our evidence and the original work from the Strätling
group (19) both indicated that a flanking AT-run aids in
vitro binding by the MBD. Despite this attempt to enrich
for favoured binding sites, we detected no MeCP2 footprints
in native chromatin. Thirdly, we found that binding of full-
length MeCP2 to this GT motif is indetectable using the
sensitive pull-down assay for MeCP2 binding (Figure 3E).
Thus, there is no in vitro precedent for an interaction of this
kind involving the native protein in vitro. In the absence of
experimental support for the notion that GT-rich sequences
are physiological ligands of full-length MeCP2 in vivo or in
vitro, the possibility that there is an undiscovered bound GT
subset becomes highly speculative.
While these results affirm the importance of cytosine
methylation for DNA binding by MeCP2, DNA sequence
specificities other than GTGT have previously been consid-
ered. Recent reports suggested that GC-content rather than
DNA methylation is the primary determinant of binding
(30). As CpG islands are GC-rich but lack DNA methy-
lation, this proposal conflicts with data from several labo-
ratories showing that MeCP2 is depleted, not enriched, at
these domains (6,8,10,25,31). It will be important to exclude
the possibility that the intrinsic base compositional bias of
DNA amplification and high throughput DNA sequencing
contribute to this discrepancy. Two AT-hook motifs (32)
contribute subtly to binding in vivo and in vitro, but appear
to be dispensable, as polymorphisms that abolish the mo-
tifs occur in the population and mutations affecting them
are absent in databases of clinically relevant mutations (33).
In addition, to these known DNA binding domains, a non-
specific affinity for DNA has been attributed to regions C-
terminal to the NID (32). It is notable, however, that mice
containing a radically truncated form of MeCP2 compris-
ing only the MBD (a.a. 72–173) and NID (a.a. 272–312)
are fully viable (15) suggesting that most of the protein, in-
cluding the putative C-terminal DNA binding domain and
AT-hooks, is non-essential.
As MeCP2 is a highly basic protein containing sev-
eral disordered regions, it is important to distinguish non-
specific DNA binding, for example due to electrostatic affin-
ity to poly-anionic DNA, from those interactions that are
specific and therefore more likely to be biologically rel-
evant. This issue is illustrated by a chromatin immuno-
precipitation study of mouse embryonic stem cells lacking
DNA methylation, which found that MeCP2 binding redis-
tributed to non-methylated sites in these cells (17). Muta-
tions in the MBD that abolish or greatly reduce binding of
MeCP2 to methylated DNA in vitro and in vivo neverthe-
less retained an association with chromatin. Despite per-
sistence of chromatin binding, however, these mutant pro-
teins cause Rett syndrome and are lethal in male mice. It
follows that residual DNA methylation-independent bind-
ing cannot compensate for the absence of specific binding
to methylated sites. Taken together, the data suggest that
motifs containing 5-methylcytosine are the primary targets
of MeCP2, predominantly in mCG and mCAC sites. Other
modes of DNA binding, where confirmed, appear to be an-
cillary to this predominant DNA binding mode and conse-
quently non-essential.
DATA AVAILABILITY
The data reported in this paper were deposited in the Gene
Expression Omnibus (GEO) database, www.ncbi.nlm.nih.
gov/geo (accession no. GSE125660).
ACKNOWLEDGEMENTS
We thank Matt Lyst and Jim Selfridge for comments on
the manuscript and members of the Bird group, past and
present, for constructive comments. We are also grateful to
Professor Malcolm Walkinshaw for many discussions on
the structure of MeCP2. In addition, we are indebted to Dr
Stuart Cobb and his laboratory for supplying the rat brains
used in this study.
FUNDING
Rett Syndrome Research Trust, a Wellcome Trust Cen-
tre [091580/Z/10/Z]; Wellcome Investigator Award
[107930/Z/15/Z]; European Research Council Advanced
[EC 694295 Gen-Epix to A.B.]; A.B. is a member of the
Simons Initiative for the Developing Brain at the University
of Edinburgh. Funding for open access charge: Wellcome
Trust.
Conflict of interest statement. None declared.
REFERENCES
1. Hashimoto,H., Zhang,X., Vertino,P.M. and Cheng,X. (2015) The
mechanisms of generation, recognition, and erasure of DNA
5-Methylcytosine and thymine oxidations. J. Biol. Chem., 290,
20723–20733.
2. He,Y. and Ecker,J.R. (2015) Non-CG methylation in the human
genome. Annu. Rev. Genomics Hum. Genet., 16, 55–77.
3. Lister,R., Mukamel,E.A., Nery,J.R., Urich,M., Puddifoot,C.A.,
Johnson,N.D., Lucero,J., Huang,Y., Dwork,A.J., Schultz,M.D. et al.
(2013) Global epigenomic reconfiguration during mammalian brain
development. Science, 341, 1237905.
4. Varley,K.E., Gertz,J., Bowling,K.M., Parker,S.L., Reddy,T.E.,
Pauli-Behn,F., Cross,M.K., Williams,B.A.,
Stamatoyannopoulos,J.A., Crawford,G.E. et al. (2013) Dynamic
DNA methylation across diverse human cell lines and tissues.
Genome Res., 23, 555–567.
5. Skene,P.J., Illingworth,R.S., Webb,S., Kerr,A.R., James,K.D.,
Turner,D.J., Andrews,R. and Bird,A.P. (2010) Neuronal MeCP2 is
expressed at near histone-octamer levels and globally alters the
chromatin state. Mol. Cell, 37, 457–468.
6. Kinde,B., Wu,D.Y., Greenberg,M.E. and Gabel,H.W. (2016) DNA
methylation in the gene body influences MeCP2-mediated gene
repression. Proc. Natl. Acad. Sci. U.S.A., 113, 15114–15119.
7. Gabel,H.W., Kinde,B., Stroud,H., Gilbert,C.S., Harmin,D.A.,
Kastan,N.R., Hemberg,M., Ebert,D.H. and Greenberg,M.E. (2015)
Disruption of DNA-methylation-dependent long gene repression in






/nar/advance-article-abstract/doi/10.1093/nar/gkaa102/5739120 by Edinburgh U
niversity user on 21 February 2020
Nucleic Acids Research, 2020 11
8. Lagger,S., Connelly,J.C., Schweikert,G., Webb,S., Selfridge,J.,
Ramsahoye,B.H., Yu,M., He,C., Sanguinetti,G., Sowers,L.C. et al.
(2017) MeCP2 recognizes cytosine methylated tri-nucleotide and
di-nucleotide sequences to tune transcription in the mammalian
brain. PLos Genet., 13, e1006793.
9. Lyst,M.J., Ekiert,R., Ebert,D.H., Merusi,C., Nowak,J., Selfridge,J.,
Guy,J., Kastan,N.R., Robinson,N.D., de Lima Alves,F. et al. (2013)
Rett syndrome mutations abolish the interaction of MeCP2 with the
NCoR/SMRT co-repressor. Nat. Neurosci., 16, 898–902.
10. Cholewa-Waclaw,J., Shah,R., Webb,S., Chhatbar,K., Ramsahoye,B.,
Pusch,O., Yu,M., Greulich,P., Waclaw,B. and Bird,A.P. (2019)
Quantitative modelling predicts the impact of DNA methylation on
RNA polymerase II traffic. Proc. Natl. Acad. Sci. U.S.A., 116,
14995–15000.
11. Amir,R.E., Van den Veyver,I.B., Wan,M., Tran,C.Q., Francke,U. and
Zoghbi,H.Y. (1999) Rett syndrome is caused by mutations in X-linked
MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet., 23,
185–188.
12. Ho,K.L., McNae,I.W., Schmiedeberg,L., Klose,R.J., Bird,A.P. and
Walkinshaw,M.D. (2008) MeCP2 binding to DNA depends upon
hydration at methyl-CpG. Mol. Cell, 29, 525–531.
13. Kruusvee,V., Lyst,M.J., Taylor,C., Tarnauskaite,Z., Bird,A.P. and
Cook,A.G. (2017) Structure of the MeCP2-TBLR1 complex reveals a
molecular basis for Rett syndrome and related disorders. Proc. Natl.
Acad. Sci. U.S.A., 114, E3243–E3250.
14. Nan,X., Meehan,R.R. and Bird,A. (1993) Dissection of the
methyl-CpG binding domain from the chromosomal protein MeCP2.
Nucleic Acids Res., 21, 4886–4892.
15. Tillotson,R., Selfridge,J., Koerner,M.V., Gadalla,K.K.E., Guy,J., De
Sousa,D., Hector,R.D., Cobb,S.R. and Bird,A. (2017) Radically
truncated MeCP2 rescues Rett syndrome-like neurological defects.
Nature, 550, 398–401.
16. Ishibashi,T., Thambirajah,A.A. and Ausio,J. (2008) MeCP2
preferentially binds to methylated linker DNA in the absence of the
terminal tail of histone H3 and independently of histone acetylation.
FEBS Lett., 582, 1157–1162.
17. Baubec,T., Ivanek,R., Lienert,F. and Schubeler,D. (2013)
Methylation-dependent and -independent genomic targeting
principles of the MBD protein family. Cell, 153, 480–492.
18. Lyst,M.J. and Bird,A. (2015) Rett syndrome: a complex disorder with
simple roots. Nat. Rev. Genet., 16, 261–275.
19. Buhrmester,H., von Kries,J.P. and Stratling,W.H. (1995) Nuclear
matrix protein ARBP recognizes a novel DNA sequence motif with
high affinity. Biochemistry, 34, 4108–4117.
20. Weitzel,J.M., Buhrmester,H. and Stratling,W.H. (1997) Chicken
MAR-binding protein ARBP is homologous to rat
methyl-CpG-binding protein MeCP2. Mol. Cell Biol., 17, 5656–5666.
21. Lei,M., Tempel,W., Chen,S., Liu,K. and Min,J. (2019) Plasticity at
the DNA recognition site of the MeCP2 mCG-binding domain.
Biochim. Biophys. Acta Gene Regul. Mech., 1862, 194409.
22. Brown,K., Selfridge,J., Lagger,S., Connelly,J., De Sousa,D., Kerr,A.,
Webb,S., Guy,J., Merusi,C., Koerner,M.V. et al. (2016) The molecular
basis of variable phenotypic severity among common missense
mutations causing Rett syndrome. Hum. Mol. Genet., 25, 558–570.
23. Piccolo,F.M., Liu,Z., Dong,P., Hsu,C.L., Stoyanova,E.I., Rao,A.,
Tjian,R. and Heintz,N. (2019) MeCP2 nuclear dynamics in live
neurons results from low and high affinity chromatin interactions.
Elife, 8, e51449.
24. Khrapunov,S., Tao,Y., Cheng,H., Padlan,C., Harris,R.,
Galanopoulou,A.S., Greally,J.M., Girvin,M.E. and Brenowitz,M.
(2016) MeCP2 binding cooperativity inhibits DNA
Modification-Specific recognition. Biochemistry, 55, 4275–4285.
25. Mellen,M., Ayata,P. and Heintz,N. (2017) 5-hydroxymethylcytosine
accumulation in postmitotic neurons results in functional
demethylation of expressed genes. Proc. Natl. Acad. Sci. U.S.A., 114,
E7812–E7821.
26. Scholz,D., Poltl,D., Genewsky,A., Weng,M., Waldmann,T.,
Schildknecht,S. and Leist,M. (2011) Rapid, complete and large-scale
generation of post-mitotic neurons from the human LUHMES cell
line. J. Neurochem., 119, 957–971.
27. Klose,R.J., Sarraf,S.A., Schmiedeberg,L., McDermott,S.M.,
Stancheva,I. and Bird,A.P. (2005) DNA binding specificity of MeCP2
due to a requirement for A/T sequences adjacent to methyl-CpG.
Mol. Cell, 19, 667–678.
28. Valinluck,V., Tsai,H.H., Rogstad,D.K., Burdzy,A., Bird,A. and
Sowers,L.C. (2004) Oxidative damage to methyl-CpG sequences
inhibits the binding of the methyl-CpG binding domain (MBD) of
methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res., 32,
4100–4108.
29. Heitmann,B., Maurer,T., Weitzel,J.M., Stratling,W.H.,
Kalbitzer,H.R. and Brunner,E. (2003) Solution structure of the
matrix attachment region-binding domain of chicken MeCP2. Eur. J.
Biochem., 270, 3263–3270.
30. Rube,H.T., Lee,W., Hejna,M., Chen,H., Yasui,D.H., Hess,J.F.,
LaSalle,J.M., Song,J.S. and Gong,Q. (2016) Sequence features
accurately predict genome-wide MeCP2 binding in vivo. Nat.
Commun., 7, 11025.
31. Chen,L., Chen,K., Lavery,L.A., Baker,S.A., Shaw,C.A., Li,W. and
Zoghbi,H.Y. (2015) MeCP2 binds to non-CG methylated DNA as
neurons mature, influencing transcription and the timing of onset for
Rett syndrome. Proc. Natl. Acad. Sci. U.S.A., 112, 5509–5514.
32. Baker,S.A., Chen,L., Wilkins,A.D., Yu,P., Lichtarge,O. and
Zoghbi,H.Y. (2013) An AT-hook domain in MeCP2 determines the
clinical course of Rett syndrome and related disorders. Cell, 152,
984–996.
33. Lyst,M.J., Connelly,J., Merusi,C. and Bird,A. (2016) Sequence







/nar/advance-article-abstract/doi/10.1093/nar/gkaa102/5739120 by Edinburgh U
niversity user on 21 February 2020
